DDInter1544 DDInter817
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status.
Gilteritinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Gilteritinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Gilteritinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pentamidine
Gilteritinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Deutetrabenazine
Gilteritinib {u} may lead to a major life threatening interaction when taken with {v} Dronedarone
Gilteritinib {u} may lead to a major life threatening interaction when taken with {v} Troleandomycin
Gilteritinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Gilteritinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine
Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Gilteritinib may lead to a major life threatening interaction when taken with Dronedarone
Gilteritinib may lead to a major life threatening interaction when taken with Troleandomycin